Table 4. Summary of the clinical trials reporting the efficacy results with crizotinib in ALK positive patients.

	pI (12,42)	pII (43,44)	pIII (45)
	crizotinib	crizotinib	crizotinib	Chemotherapy (PEM+DOC)
n	82 [119]	135 [261]	173	174
Overall RR (%)	61%	51%	65%	20% (PEM29%; DOC6.9%)	P<0.001
Duration of response (median, weeks)	48	42.9
Duration of treatmente (median, weeks or cycles)	32 w	22 w	11 cycles	4 cycles
6 months PFS	72%	NR	NR	NR
mPFS (median, months)	NR	8.1 (6.8-9.7)	7.7	3 (PEM4.2; DOC2.6)	HR 0.49 (0.37-0.64), P<0.0001
mOS	NR	NR	20.3	22.8	HR 1.02 (0.68-1.5), P=0.5394
OS rates 6 m, 12 m	NR	90%, 81%	NR	NR

DOC, docetaxel; m, months; m-PFS, median progression-free survival; mOS, median overall survival; n, number of patients included; PEM, pemetrexed; NR, no reported; RR, response rate; w, weeks